TEXT 102770

PTO-1590 (8-01)

So	cientific and Technic	al Information Center	
Requester's Full Name: Baz Aft Únit: 1641 Phone Mail Box and Bldg/Room Locatio	Number 30 8 - 421 n: Res	Examiner # : 73403 13 Serial Number: 09, Sults Format Preferred (circle):	Date: 8/25/03 845,726 PAPER DISK E-MAIL
If more than one search is subn			
Please provide a detailed statement of the Include the elected species or structures, utility of the invention. Define any terms known. Please attach a copy of the cover	search topic, and describe keywords, synonyms, acro that may have a special n	e as specifically as possible the subjoryms, and registry numbers, and concaring. Give examples or relevant	ect matter to be searched.
Title of Invention: Biopo	lymarker.		
Inventors (please provide full names):	Jackows	iki et al	
Earliest Priority Filing Date:	4/30/01 1	The second of	
*For Sequence Searches Only* Please inclu		(parent, child, divisional, or issued no	tent numbers) along with the
appropriate serial number.	p sources anyou manon	nerisional, or issued pu	the state of the s
please Searc	h SEQ II	NO.1 Spec	ifically
'résidues	2-12.		,
•			, , , ,
. please al	so searce	h pending d	atabasl
& inventor.		The side of the si	V
77.7		77	,
*		Mank You	u.
L. L.			
1-11 max	·· -		
			(10)
STAFF USE ONLY	Type of Search	**************************************	**************************************
Searcher: Hanly	NA Sequence (#)	STN	
Searcher Phone #:	AA Sequence (#)	Dialog	,
Searcher Location:	Structure (#)	Questel/Orbit	
Date Searcher Picked Up: 8/2	Bibliographic	Dr.Link	
Date Completed:	Litigation	Lexis/Nexis	
Searcher Prep & Review Time: SER 10 151	N Fulltext	Sequence Systems	
Clerical Prep Time:	Patent Family	WWW/Internet	<del></del>
Online Time: -17)	Other	Other (specify)	

BEST AVAILABLE COPY



# STIC Search Report Biotech-Chem Library

# STIC Database Tracking Number: 102274

TO: Bao-thuy Nguyen Location: CM1/7E05

**Art Unit: 1641** 

Friday, August 29, 2003

Case Serial Number: 09845726

From: Susan Hanley

**Location: Biotech-Chem Library** 

CM1 6B05

Phone: 305-4053

susan.hanley@uspto.gov

Search Notes	
	_
,	
	·
	•
×	
	•
	·
	·
	•
•	
·	



```
=> d his
```

```
(FILE 'HOME' ENTERED AT 17:40:20 ON 29 AUG 2003)
     FILE 'CAPLUS' ENTERED AT 17:40:28 ON 29 AUG 2003
             153 S JACKOWSKI G?/AU
L1
L2
              35 S STANTON E?/AU
L3
              48 S THATCHER B?/AU
              31 S YANTHA J?/AU
L4
            3032 S MARSHALL J?/AU
L5
            3170 S L1-5
L6
              58 S L6 AND BIOPOLYMER
17
L8
              89 S L6 AND MOLECULAR WEIGHT
              29 S L7 AND L8 = 29 cites
L9
                 SELECT RN L9 1-29
     FILE 'REGISTRY' ENTERED AT 17:42:57 ON 29 AUG 2003
L10
              29 S E1-29
                            29 cpds for L9 cites
     FILE 'CAPLUS' ENTERED AT 17:43:25 ON 29 AUG 2003
                                  29 cites & 29 apds displayed
L11
              29 S L10 AND L9
=> d ibib abs hitstr 1-29
L11 ANSWER 1 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                           2002:849935 CAPLUS
DOCUMENT NUMBER:
                           137:348846
TITLE:
                           Biopolymer marker indicative of disease
                           state having a molecular weight of
                           1845 daltons
                           Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;
INVENTOR(S):
                           Vrees, Tammy
                           Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
SOURCE:
                           PCT Int. Appl., 27 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND
                             DATE
                                              APPLICATION NO.
     WO 2002088747
                        A2
                             20021107
                                              WO 2002-CA633
                                                                 20020429
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2003013845
                        A1 20030116
                                              US 2001-846351
                                                                20010430
PRIORITY APPLN. INFO.:
                                           US 2001-846351 A 20010430
    The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     the absence of said at least one disease state relative to recognition of
     the presence and/or the absence of said biopolymer.
IT
     473553-05-8
```

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL

(Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 1845 daltons)  $\,$ 

RN

473553-05-8 CAPLUS
L-Arginine, L-arginyl-L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-L-alanyl-L-leucyl-L-glutaminyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-glutaminyl-L-isoleucyl- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.

### PAGE 2-A

### PAGE 3-A

### PAGE 4-A

```
L11 ANSWER 2 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:849925 CAPLUS

DOCUMENT NUMBER: TITLE:

137:348845

Biopolymer marker indicative of disease

state having a molecular weight of

1211 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Syn.X Pharma, Inc., Can. PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION: 1

PA	FENT	NO.		KI	ND	DATE			A	PPLI	CATI	ON N	0.	DATE			
									-								
WO	2002	0887	31	A.	2	2002	1107		W	0 20	02-C	A632		2002	0429		
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		СО,	CR,	CU,	CZ,	DΕ,	DK,	DM,	DΖ,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,
		HR,	ΗU,	ID,	IL,	IN,	IS,	JΡ,	ΚE,	KG,	KΡ,	KR,	ΚZ,	LC,	LK,	LR,	LS,
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	ΝZ,	PL,	PT,	RO,
		RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	Π,	TZ,	UA,	UG,	UΖ,	VN,
		YU,	ZA,	ZW,	ΑM,	ΑZ,	ΒY,	KG,	ΚZ,	MD,	RU,	TJ,	TM				
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,

### NGUYEN 09/845,726

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2003004307 A1 20030102 US 2001-845731 20010430
PRIORITY APPLN. INFO.: US 2001-845731 A 20010430

PRIORITY APPLN. INFO.:

US 2001-845731 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-light detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 473553-28-5

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

RN 473553-28-5 CAPLUS

CN L-Leucine, L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

```
ACCESSION NUMBER:
                            2002:849924 CAPLUS
DOCUMENT NUMBER:
                            137:348844
TITLE:
                            Biopolymer marker indicative of disease
                            state having a molecular weight of
                            1690 daltons
INVENTOR(S):
                            Jackowski, George: Thatcher, Brad:
                            Vrees, Tammy; Yantha, Jason; Marshall,
                            John
                            Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
                            PCT Int. Appl., 30 pp.
SOURCE:
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
LANGUAGE:
                            English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND DATE
                                                APPLICATION NO. DATE
     WO 2002088727
                         A2
                               20021107
                                                WO 2002-CA617
                                                                   20020429
     WO 2002088727
                         Α3
                               20030103
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2002169278
                         Α1
                               20021114
                                                US 2001-845730
                                                                  20010430
     US 6593298
                         В2
                               20030715
PRIORITY APPLN. INFO.:
                                            US 2001-845730 A 20010430
    The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer.
TT
     473552-58-8
     RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL
     (Biological study); USES (Uses)
```

(biopolymer marker indicative of disease state having a

L-Leucine, L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-

Absolute stereochemistry.

RN

473552-58-8 CAPLUS

mol. wt. of 1690 daltons)

leucyl- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

Come

L11 ANSWER 4 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:849923 CAPLUS

DOCUMENT NUMBER:

137:348791

TITLE:

Biopolymer marker indicative of disease

state having a molecular weight of

1406 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Vrees, Tammy; Yantha, Jason; Marshall,

PATENT ASSIGNEE(S):

SOURCE:

Syn.X Pharma, Inc., Can.

PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002088723	A2	20021107	WO 2002-CA611	20020426
WO 2002088723	A3	20030103		
W: AE, AG,	AL, AM,	, AT, AU, AZ,	BA, BB, BG, BR, BY	, BZ, CA, CH, CN,
CO CR.	CU CZ	DE DK DM	DZ FC FF FS FT	GR GD GE GH

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2003040602 A1 20030227 US 2001-846347 20010430

PRIORITY APPLN. INFO.:

US 2001-846347 A 20010430

AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

IT 263562-85-2

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 1406 daltons)

RN 263562-85-2 CAPLUS

CN L-Lysine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 5 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:849922 CAPLUS

```
DOCUMENT NUMBER:
                             137:348843
TITLE:
                             Biopolymer marker indicative of disease
                             state having a molecular weight of
                                                                      Same
                             2056 daltons
                            Jackowski, George; Thatcher, Brad;)
Marshall, John; Yantha, Jason;
INVENTOR(S):
                             Vrees, Tammy
                             Syn.X Pharma, Inc., Can.
PATENT ASSIGNEE(S):
                             PCT Int. Appl., 27 pp.
SOURCE:
                             CODEN: PIXXD2
DOCUMENT TYPE:
                             Patent
                             English
LANGUAGE:
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                                                 APPLICATION NO.
                         KIND
                                DATE
     WO 2002088717
                                20021107
                                                 WO 2002-CA578
                          A2
                                                                     20020425
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
          PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                              US 2001-845736
PRIORITY APPLN. INFO.:
                                                                A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer.
     112805-24-0, Complement C3f (human)
```

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a

mol. wt. of 2056 daltons)

RN 112805-24-0 CAPLUS


CN Complement C3f (human) (9CI) (CA INDEX NAME)

PAGE 1-A

HO'

PAGE 1-B

PAGE 2-B



L11 ANSWER 6 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:849921 CAPLUS

DOCUMENT NUMBER:

137:348842

TITLE:

Polymer marker indicative of disease state having a

INVENTOR(S):

Sul molecular weight of 1518 daltons. Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

PATENT ASSIGNEE(S):

Vrees, Tammy Syn.X Pharma, Inc., Can. PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

SOURCE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE WO 2002088716 20021107 WO 2002-CA577 A2 20020425 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845765 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. 25422-31-5, Fibrinopeptide A (human) RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (polymer marker indicative of disease state having a mol. wt. of 1518 daltons) RN 25422-31-5 CAPLUS

Absolute stereochemistry.

PAGE 1-A

Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME)

PAGE 1-B

PAGE 2-B

CO<sub>2</sub>H

L11 ANSWER 7 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833556 CAPLUS

DOCUMENT NUMBER:

137:334916

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

INVENTOR(S):

molecular weight of 1020 daltons Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

Searched by Susan Hanley 305-4053

```
US 2002161188
                        A1
                              20021031
                                              US 2001-846350
                                                                20010430
     US 659987.7
                        B2
                              20030729
     WO 2002088728
                        A2
                              20021107
                                              WO 2002-CA619
                                                                20020429
     WO 2002088728
                        Α3
                              20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                           US 2001-846350
PRIORITY APPLN. INFO.:
                                                           A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence DFLAEGGGVR and
     characterized as a .alpha. fibrinogen having a mol. wt
      . of 1020 daltons was found. This marker is indicative of myocardial
     infarction.
     59001-25-1, 7-16-Fibrinopeptide A (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (alpha fibrinogen biopolymer marker of 1020 daltons
        indicative of myocardial infarction)
RN
     59001-25-1 CAPLUS
     7-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833555 CAPLUS

DOCUMENT NUMBER:

137:334915

TITLE:

Apolipoprotein CIII biopolymer marker indicative of Type II diabetes having a molecular weight of 1097 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

Can.

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATEN	Г NO.	KIND	DATE		APPLI	CATION	NO.	DATE				
WO 20	02161187 02088743 02088743	A1 A2	20021107			01-846 02-CA6		20010430 20020429				
W	: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, V: GH, GM, CY, DE,	AL, AM CU, CZ HU, ID LU, LV RO, RU UZ, VN KE, LS DK, ES	, AT, AU, , DE, DK, , IL, IN, , MA, MD, , SD, SE, , YU, ZA, , MW, MZ, , FI, FR,	AZ,   DM,   IS,   MG,   SG,   SZM,   SD,   SG,   SG,   SD,   SG,   SD,   SD,	DZ, EC, JP, KE, MK, MN, SI, SK, ZW, AM, SL, SZ, GR, IE,	EE, E KG, H MW, M SL, T AZ, E TZ, U	ES, FI, KP, KR, MX, MZ, TJ, TM, BY, KG, JG, ZM, LU, MC,	, GB, , KZ, , NO, , TN, , KZ, , ZW,	GD, GLC, I NZ, G TR, T MD, I AT, I PT, S	GE, LK, OM, TT, RU, BE, SE,	GH, LR, PH, TZ, TJ, CH, TR,	тм
PRIORITY A			, CI, CM,							ΓD,	TG	
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.:  US 2001-846352 A 20010430  AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence PEVRPTSAVAA and characterized as a apolipoprotein CIII having a mol. wt  of 1097 daltons was found. This marker is indicative of Type II											to e	
RL: A use);	D-31-1 NT (Analyt PRP (Prop (Uses)											

(apolipoprotein CIII biopolymer marker of 1097 daltons indicative of Type II diabetes)

473550-31-1 CAPLUS RN

L-Alanine, L-prolyl-L-.alpha.-glutamyl-L-valyl-L-arginyl-L-prolyl-L-CN threonyl-L-seryl-L-alanyl-L-valyl-L-alanyl- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.

PAGE 1-A HN (CH<sub>2</sub>)<sub>3</sub>

PAGE 1-B

L11 ANSWER 9 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833554 CAPLUS

DOCUMENT NUMBER:

137:334914

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure

having a molecular weight of 1449

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161186	A1	20021031	US 2001-846349	20010430
US 6602855	B2	20030805		
WO 2002088726	A2	20021107	WO 2002-CA615	20020426
WO 2002088726	A3	20021227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, CM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, PRIORITY APPLN. INFO.: US 2001-846349 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence THRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1449 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure. 112821-21-3, Complement C3f RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 112821-21-3 CAPLUS

CN Complement C3f (9CI) (CA INDEX NAME)

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 473549-42-7

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(complement C3f biopolymer marker of 1449 daltons indicative of myocardial infarction and congestive heart failure)

RN 473549-42-7 CAPLUS

CN L-Leucine, L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

PAGE 1-B

```
L11 ANSWER 10 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:833553 CAPLUS

DOCUMENT NUMBER:

137:334913

TITLE:

Alpha fibrinogen biopolymer marker

indicative of renal failure having a molecular weight of 1206 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

Can.

PATENT ASSIGNEE(S): SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE				
US 2002161185 WO 2002088721	A2	20021107	US 2001-845725 WO 2002-CA609					
CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, RW: GH, GM, CY, DE, BF, BJ, PRIORITY APPLN. INFO AB The instant involutes to many verifiable with verified within evidence at lead diagnostician to absence of said presence and/or were analyzed by disease specific	AL, AM CU, CZ HU, ID LU, LV RO, RU UZ, VN KE, LS DK, ES CF, CG :: ention we aximize in a pa st one o gain at lea y SELDI c marke	, AT, AU, AZ, DE, DK, DM, IL, IN, IS, MA, MD, MG, SD, SE, SG, YU, ZA, ZM, MW, MZ, SD, FI, FR, GB, CI, CM, GA  involves the diversiticular sample is the diversiticular sample is the ability st one diseasence of said-TOF using the identified	, SL, SZ, TZ, UG, ZM, GR, IE, IT, LU, MC, GN, GQ, GW, ML, MR US 2001-845725 A use of a combinatio ctroscopy and time-oty of biopolymers whole. The cohort of men viewed with ref. isease state; thereb to characterize eith se state relative to dipopolymer. Serum	, GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ, , KZ, MD, RU, TJ, TM , ZW, AT, BE, CH, , NL, PT, SE, TR, , NE, SN, TD, TG 20010430 n of preparatory f-flight detection ich are biopolymers to their ability to y enabling a er the presence or recognition of the samples CHIP system and the FLAEGGGVR and				

. of 1206 daltons was found. This marker is indicative of renal failure.

**59001-24-0**, 5-16-Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1206 daltons

indicative of renal failure)

RN 59001-24-0 CAPLUS

CN 5-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 11 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833552 CAPLUS

DOCUMENT NUMBER:

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure having a molecular weight of 1348

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can. U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE:

**Patent** 

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
US 2002161184	A1	20021031	US 2001-845715	20010430		
WO 2002088720	A2	20021107	WO 2002-CA608			

WO 2002088720 Α3 20030206 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845715 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence HRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1348 daltons was found. This marker is indicative of myocardial infarction, intracerebral hemorrhage, or congestive heart failure. IT 112821-21-3, Complement C3f RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 473546-75-7 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

IT

use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);

(complement C3f biopolymer marker of 1348 daltons indicative of myocardial infarction and congestive heart failure)

RN 473546-75-7 CAPLUS

L-Leucine, L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A Мe CO<sub>2</sub>H Et Bu-i

PAGE 1-B

```
L11 ANSWER 12 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:833551 CAPLUS

DOCUMENT NUMBER:

137:334911

TITLE:

Apolipoprotein E biopolymer marker

INVENTOR(S):

indicative of insulin resistance having a molecular weight of 2267 daltons
Jackowski, George; Thatcher, Brad;
Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can. U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND D	ATE	APPLICATION NO.	DATE					
US 2002161183 WO 2002088745	A2 2	0021107	US 2001-846348 WO 2002-CA624						
CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, RW: GH, GM, CY, DE,	AL, AM, ACU, CZ, HU, ID, LU, LV, IRO, RU, UZ, VN, KE, LS, IDK, ES, CF, CG, 6	AT, AU, AZ, B DE, DK, DM, D IL, IN, IS, J MA, MD, MG, M SD, SE, SG, S YU, ZA, ZM, Z MW, MZ, SD, S FI, FR, GB, G CI, CM, GA, G	A, BB, BG, BR, BY Z, EC, EE, ES, FI P, KE, KG, KP, KR K, MN, MW, MX, MZ I, SK, SL, TJ, TM W, AM, AZ, BY, KG L, SZ, TZ, UG, ZM R, IE, IT, LU, MC N, GQ, GW, ML, MR 2001-846348 A	, GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ, , KZ, MD, RU, TJ, TM , ZW, AT, BE, CH, , NL, PT, SE, TR, , NE, SN, TD, TG					
AB The instant inv steps in conjun procedures to m verifiable with verified within evidence at lea diagnostician t absence of said presence and/or were analyzed b disease specifi	ention in ction with aximize the such a such a such a such at least the absety SELDI-To marker	volves the us h mass spectre diversity icular sample ample is then rticular dise e ability to one disease nce of said bOF using the identified by	e of a combinatio oscopy and time-o of biopolymers wh . The cohort of viewed with ref. ase state; thereb characterize eith state relative to iopolymer. Serum Ciphergen PROTEIN	n of preparatory f-flight detection ich are biopolymers to their ability to y enabling a er the presence or recognition of the samples CHIP system and the SLAGQPLQERAQAWGERL					

. of 2267 daltons was found. This marker is indicative of insulin resistance.

IT 473546-72-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(apolipoprotein E biopolymer marker indicative of insulin resistance having a mol. wt. of 2267 daltons)

RN 473546-72-4 CAPLUS

CN L-Leucine, L-threonyl-L-valylglycyl-L-seryl-L-leucyl-L-alanylglycyl-L-glutaminyl-L-prolyl-L-leucyl-L-glutaminyl-L-.alpha.-glutamyl-L-arginyl-L-alanyl-L-glutaminyl-L-alanyl-L-tryptophylglycyl-L-.alpha.-glutamyl-L-arginyl- (9CI) (CA INDEX NAME)

PAGE 1-B

PAGE 2-A

PAGE 2-B HN ΗŃ Bu-i

PAGE 2-C

9004-10-8, Insulin, biological studies

RL: ADV (Adverse effect, including toxicity); BSU (Biological study,

unclassified); BIOL (Biological study)

(resistance; apolipoprotein E biopolymer marker indicative of

insulin resistance having a mol. wt. of 2267

daltons)

9004-10-8 CAPLUS RN

Insulin (9CI) (CA INDEX NAME) CN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L11 ANSWER 13 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833550 CAPLUS

DOCUMENT NUMBER: TITLE:

137:334910

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure

having a molecular weight of 1865

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

SOURCE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
20021031
                                              US 2001-846345
                                                                 20010430
     US 2002161182
                        A1
                                              WO 2002-CA622
                              20021107
                                                                 20020429
     WO 2002088174
                        Α2
     WO 2002088174
                        A3
                              20030116
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                           US 2001-846345
                                                             A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLL and
     characterized as a complement C3f fragment having a mol.
     wt. of 1865 daltons was found. This marker is indicative of
     myocardial infarction, intracerebral hemorrhage, Type II diabetes, or
     congestive heart failure.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (complement C3f biopolymer marker of 1865 daltons indicative
        of myocardial infarction and congestive heart failure)
RN
     112821-21-3 CAPLUS
     Complement C3f (9CI) (CA INDEX NAME)
CN
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     473546-71-3
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C3f biopolymer marker of 1865 daltons indicative
        of myocardial infarction and congestive heart failure)
     473546-71-3 CAPLUS
RN
     L-Leucine, L-seryl-L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-
     arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-
     alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)
```

### PAGE 1-A

### PAGE 1-B

L11 ANSWER 14 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833549 CAPLUS

DOCUMENT NUMBER: TITLE:

137:334909 Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure

having a molecular weight of 2021

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can. SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
US 2002161181
                             20021031
                                             US 2001-846344
                       A1
                                                               20010430
                                             WO 2002-CA627
                             20021107
     WO 2002088711
                        A2
                                                               20020429
     WO 2002088711
                        Α3
                             20030116
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                          US 2001-846344
                                                           A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLLR and
     characterized as a complement C3f fragment having a mol.
     wt. of 2021 daltons was found. This marker is indicative of
     myocardial infarction, Type II diabetes, or congestive heart failure.
     112821-21-3, Complement C3f
TT
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (complement C3f biopolymer marker of 2021 daltons indicative
        of myocardial infarction and congestive heart failure)
     112821-21-3 CAPLUS
RN
CN
     Complement C3f (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     112805-24-0, Complement C3f (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C3f biopolymer marker of 2021 daltons indicative
        of myocardial infarction and congestive heart failure)
     112805-24-0 CAPLUS
RN
     Complement C3f (human) (9CI) (CA INDEX NAME)
CN
Absolute stereochemistry.
```

PAGE 1-A

H0<sup>-</sup>

PAGE 1-B

PAGE 2-B

L11 ANSWER 15 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:833548 CAPLUS

DOCUMENT NUMBER:

137:334908

TITLE:

Complement C4A biopolymer marker indicative

### NGUYEN 09/845,726

```
of myocardial infarction and congestive heart failure
                           having a molecular weight of 1896
                           daltons
INVENTOR(S):
                           Jackowski, George; Thatcher, Brad;
                                                                   garel
                           Marshall, John; Yantha, Jason;
                           Vrees, Tammy
PATENT ASSIGNEE(S):
                           Can.
SOURCE:
                           U.S. Pat. Appl. Publ., 10 pp.
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND
                              DATE
                                               APPLICATION NO.
                                                                 DATE
     US 2002161180
                              20021031
                         Α1
                                               US 2001-846343
                                                                  20010430
     WO 2002088724
                         A2
                              20021107
                                               WO 2002-CA612
                                                                  20020426
     WO 2002088724
                         Α3
                              20030103
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                           US 2001-846343 A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence NGFKSHALQLNNRQIR and
     characterized as a complement C4A fragment having a mol.
     wt. of 1896 daltons was found. This marker is indicative of
     myocardial infarction, Type II diabetes, and congestive heart failure.
     80295-48-3, Complement C4
TT
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
        (C4A; complement C4A biopolymer marker of 1896 daltons
        indicative of myocardial infarction and congestive heart failure)
RN
     80295-48-3 CAPLUS
CN
     Complement C4 (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     473546-69-9
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (complement C4A biopolymer marker of 1896 daltons indicative
        of myocardial infarction and congestive heart failure)
RN
     473546-69-9 CAPLUS
CN
     L-Arginine, L-asparaginylglycyl-L-phenylalanyl-L-lysyl-L-seryl-L-histidyl-
     L-alanyl-L-leucyl-L-glutaminyl-L-leucyl-L-asparaginyl-L-asparaginyl-L-
     arginyl-L-glutaminyl-L-isoleucyl- (9CI) (CA INDEX NAME)
```

### PAGE 1-A

## PAGE 1-B

# PAGE 2-A

PAGE 3-A

PAGE 4-A

L11 ANSWER 16 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:833547 CAPLUS 137:334907

TITLE:

Alpha fibrinogen biopolymer marker

indicative of renal failure or intracerebral

hemorrhage having a molecular weight

of 1465 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy Can.

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PΔ	PATENT NO.					DATE			APPLICATION NO.									
	TATEM NO.								ATTEICATION NO.					DATE				
US	IS 2002161179 A1			20021031				US 2001-845719				20010430						
WC	2002	0887	15	A2	2	2002	1107		W	200	02-C	A576		20020425				
WC	2002	0887	15	A:	3	2003	0116											
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	ΒA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
						DE,												
						IL,												
						MA,												
		PL,	PΤ,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	Π,	TZ,	
						YŪ,												TM
	RW:					MW,												
		CY,	DE,	DK,	ES,	FΙ,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PΤ,	SE,	TR,	
						CI,											TG	
PRIORIT						_												
	e ins																	
st	eps i	n co	njun	ctio	n wi	th ma	ass	spec	tros	сору	and	tim	e-of	-fli	ght	dete	ction	1
	ocedu																	
ve	rifia	ble	with	in a	par	'ticu	lar	samp	le.	The	coh	ort	of b	iopo	lyme	rs		

verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DSGEGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt
. of 1465 daltons was found. This marker is indicative of renal failure

or intracerebral hemorrhage.

IT 107012-96-4, 2-16-Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1465 daltons indicative of renal failure or intracerebral hemorrhage)

RN 107012-96-4 CAPLUS

CN 2-16-Fibrinopeptide A (human) (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-C

```
S CO2H
```

```
L11 ANSWER 17 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                         2002:833546 CAPLUS
DOCUMENT NUMBER:
                         137:334906
TITLE:
                         Serum albumin biopolymer marker indicative
                         of insulin resistance having a molecular
                         weight of 2937 daltons
INVENTOR(S):
                         Jackowski, George; Thatcher, Brad;
                         Marshall, John; Yantha, Jason;
                         Vrees, Tammy
PATENT ASSIGNEE(S):
                         Can.
SOURCE:
                         U.S. Pat. Appl. Publ., 10 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:
                         Patent
LANGUAGE:
                         English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
    PATENT NO.
                     KIND DATE
                                           APPLICATION NO.
                                                            DATE
                                              ------
    US 2002161177
                      A1
                            20021031
                                           US 2001-846329
    WO 2002088742
                      A2
                            20021107
                                           WO 2002-CA613
```

```
20010430
                                                                   20020426
     WO 2002088742
                         Α3
                               20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
              UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
PRIORITY APPLN. INFO.:
                                             US 2001-846329 A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence
     DAHKSEVAHRFKDLGEENFKALVLIA and characterized as a serum albumin having a
     mol. wt. of 2937 daltons was found. This marker is
     indicative of insulin resistance.
IT
     9004-10-8, Insulin, biological studies
     RL: ADV (Adverse effect, including toxicity); BSU (Biological study,
     unclassified); BIOL (Biological study)
         (resistance; serum albumin biopolymer marker of 2937 daltons
        indicative of insulin resistance)
     9004-10-8 CAPLUS
     Insulin (9CI) (CA INDEX NAME)
CN
```

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

IT 473546-58-6

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum albumin biopolymer marker of 2937 daltons indicative of insulin resistance)

RN 473546-58-6 CAPLUS

CN

L-Alanine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-alpha.-glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-L-leucyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

### PAGE 1-C

### PAGE 1-D

### PAGE 2-D

\_\_Et

```
ACCESSION NUMBER:
                           2002:833503 CAPLUS
DOCUMENT NUMBER:
                           137:334905
TITLE:
                           Serum albumin biopolymer marker indicative
                          of renal failure having a molecular
                           weight of 1521 daltons
INVENTOR(S):
                           Jackowski, George; Thatcher, Brad;
                           Marshall, John; Yantha, Jason;
                           Vrees, Tammy
PATENT ASSIGNEE(S):
                           Can.
                           U.S. Pat. Appl. Publ., 10 pp.
SOURCE:
                           CODEN: USXXCO
DOCUMENT TYPE:
                           Patent
LANGUAGE:
                           English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
    PATENT NO.
                       KIND DATE
                                              APPLICATION NO.
                                                                 DATE
    US 2002160958
                        A1
                              20021031
                                              US 2001-845764
                                                                 20010430
    WO 2002088713
                              20021107
                                              WO 2002-CA631
                        A2
                                                                 20020429
     WO 2002088713
                        Α3
                              20021227
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
         UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                           US 2001-845764
                                                            A 20010430
    The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence DAHKSEVAHRFKD and
     characterized as a serum albumin having a mol. wt. of
     1521 daltons was found. This marker is indicative of renal failure.
TT
     473552-37-3
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (serum albumin biopolymer marker of 1521 daltons indicative
        of renal failure)
RN
     473552-37-3 CAPLUS
     L-Aspartic acid, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-
CN
     .alpha.-qlutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-
     lysyl- (9CI) (CA INDEX NAME)
```

L11 ANSWER 18 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

PAGE 1-A

PAGE 1-B

ΙT 474276-98-7

RL: PRP (Properties)

(unclaimed sequence; serum albumin biopolymer marker indicative of renal failure having a mol. wt. of

1521 daltons)

RN 474276-98-7 CAPLUS

L-Leucine, L-arginyl-L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-CN

seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

```
(CH<sub>2</sub>)<sub>4</sub>
     i-Pr
                                                               (CH<sub>2</sub>)<sub>3</sub>
                                                                                             NH2 HN
_со₂н ö
                                                                                    HO<sub>2</sub>C.
                             Мe
                                                                                                               0
                                                                                                                             C02H
```

L11 ANSWER 19 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833430 CAPLUS

DOCUMENT NUMBER:

137:334904

TITLE:

Serum amyloid A biopolymer marker indicative of myocardial infarction having a molecular

weight of 1525 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT:

	PAT	ENT I			KI	۱D	DATE			AF	PLI	CATIO	ON NO	0.	DATE				
						-													
		2002											4677	_		0430		•	
		2002								WC	200	)2-C/	٩630		2002	0429			
	WO	2002	0887	30	A:	3	2002	1227											
	WO	2002	0887	30	C:	L	20030	3320											
		W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN.	
							DE,												
			GM.	HR.	HU.	ID.	IL,	IN.	IS.	JP.	KE.	KG.	KP.	KR.	KZ.	LC.	LK.	LR.	
							MA,				•	•		•			-		
							SD,												
							YŪ,												тм
		RW.					MW,												11.1
		IVW .					FI,												
							ĊĨ,												
PRIO	) T T\	A D D				cu,											ıυ,	10	
-										JS 20			-				<b>.</b>		
AB		ins																	
		ps i															jetec	ction	1
	•	cedu										•							
		ifial																	
		ifie																lity	to
		dence																	
	dia	gnos	ticia	an to	ga <sup>-</sup>	in t	he al	oili:	ty to	o cha	aract	teri	ze e	ithe	r th	e pre	esend	ce or	r

absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence PNHFRPAGLPEKY and characterized as a serum amyloid A having a mol. wt. of 1525 daltons was found. This marker is indicative of myocardial infarction.

IT 331450-30-7

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum amyloid A biopolymer marker of 1525 daltons indicative of myocardial infarction)

RN 331450-30-7 CAPLUS

CN L-Tyrosine, L-prolyl-L-asparaginyl-L-histidyl-L-phenylalanyl-L-arginyl-L-prolyl-L-alanylglycyl-L-leucyl-L-prolyl-L-alpha.-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 20 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:833429 CAPLUS

DOCUMENT NUMBER: 137:334903

TITLE:

Complement C3f biopolymer marker indicative

of Type II diabetes having a molecular

weight of 1998 daltons

INVENTOR(S):
Jackowski, George; Thatcher, Brad;

```
Marshall, John; Yantha, Jason;
                            Vrees, Tammy
PATENT ASSIGNEE(S):
                            Can.
                            U.S. Pat. Appl. Publ., 10 pp.
SOURCE:
                            CODEN: USXXCO
DOCUMENT TYPE:
                            Patent
LANGUAGE:
                            English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                        KIND DATE
                                                APPLICATION NO. DATE
                                                   . . . . . . . . . . . . .
     US 2002160532
                         Α1
                               20021031
                                                US 2001-846346
                                                                   20010430
     WO 2002088707
                               20021107
                                                WO 2002-CA616
                                                                   20020429
                         Α2
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
              CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             US 2001-846346
PRIORITY APPLN. INFO.:
                                                               A 20010430
     The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SSKITHRIHWESASLLR and
     characterized as a complement C3f fragment having a mol.
     wt. of 1998 daltons was found. This marker is indicative of Type
     II diabetes.
     112821-21-3, Complement C3f
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
         (complement C3f biopolymer marker of 1998 daltons indicative
         of type II diabetes)
RN
     112821-21-3 CAPLUS
CN
     Complement C3f (9CI) (CA INDEX NAME)
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
     112805-24-0, Complement C3f (human)
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
```

(complement C3f biopolymer marker of 1998 daltons indicative

Absolute stereochemistry.

RN

of type II diabetes) 112805-24-0 CAPLUS

Complement C3f (human) (9CI) (CA INDEX NAME)

PAGE 1-A

H0'

PAGE 1-B

PAGE 2-B

L11 ANSWER 21 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN ACCESSION NUMBER: 2002:833428 CAPLUS

DOCUMENT NUMBER:

137:333522

TITLE:

Biopolymer marker indicative of disease

state having a molecular weight of

2753 daltons

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; INVENTOR(S):

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

SOURCE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO KIND	DATE APPLICATION NO.	DATE					
US 2002160531 A1	20021031 US 2001-846328	20010430					
WO 2002088710 A2	20021107 WO 2002-CA626	20020429					
WO 2002088710 A3	20021227						
	AT, AU, AZ, BA, BB, BG, BR, B	Y RZ CA CH CN					
	DE, DK, DM, DZ, EC, EE, ES, F						
	IL, IN, IS, JP, KE, KG, KP, K						
	MA, MD, MG, MK, MN, MW, MX, M						
	SD, SE, SG, SI, SK, SL, TJ, T						
	YU, ZA, ZM, ZW, AM, AZ, BY, K						
RW: GH, GM, KE, LS,	MW, MZ, SD, SL, SZ, TZ, UG, Z	4, ZW, AT, BE, CH,					
CY, DE, DK, ES,	FI, FR, GB, GR, IE, IT, LU, M	C, NL, PT, SE, TR,					
BF. BJ. CF. CG.	CI, CM, GA, GN, GQ, GW, ML, M	R. NE. SN. TD. TG					
	US 2001-846328 A						
	nvolves the use of a combination						
	th mass spectroscopy and time-						
	the diversity of <b>biopolymers</b> w						
•							
•	ticular sample. The cohort of						
	sample is then viewed with ref						
evidence at least one particular disease state; thereby enabling a							
diagnostician to gain t	he ability to characterize eit	ner the presence or					
absence of said at leas	t one disease state relative t	recognition of the					
presence and/or the absence of said biopolymer.							

98420-25-8 IT

RL: ANT (Analyte); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(biopolymer marker indicative of disease state having a mol. wt. of 2753 daltons)

98420-25-8 CAPLUS RN

L-Leucine, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-Llysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl-L-.alpha.glutamyl-L-asparaginyl-L-phenylalanyl-L-lysyl-L-alanyl-L-leucyl-L-valyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-C

PAGE 2-C

IT 9004-10-8, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; biopolymer marker indicative of disease state
having a mol. wt. of 2753 daltons)

RN 9004-10-8 CAPLUS

CN Insulin (9CI) (CA INDEX NAME)

# \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* L11 ANSWER 22 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833426 CAPLUS

DOCUMENT NUMBER:

137:334902

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction or congestive heart failure

having a molecular weight of 1562

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall,

John Can.

PATENT ASSIGNEE(S):

SOURCE:

RN CN U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English 1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

	PATENT NO.	KIND	DATE		APPLI	CATION	NO.	DATE			
	US 2002160529 WO 2002088729 WO 2002088729	A1 A2	20021031 20021107 20021227			01-8457 02-CA62		20010430 20020429			
	CO, CR, GM, HR,	CU, CZ HU, ID	, AT, AU, , DE, DK, , IL, IN,	DM, DZ	Z, EC, P, KE,	EE, ES KG, KP	, FI,	, GB, GD, , KZ, LC,	GE, LK,	GH, LR,	
	PL, PT,	RO, RU	, MA, MD, , SD, SE,	SG, SI	I, SK,	SL, TJ	, TM	TN, TR,	Π,	TZ,	
	RW: GH, GM, CY, DE,	KE, LS DK, ES	, FI, FR,	SD, SI	., SZ, ≷, IE,	TZ, UG IT, LU	, ZM,	, ZW, AT, , NL, PT,	BE, SE,	CH, TR,	TM
PRTO	BF, BJ, RITY APPLN. INFO	CF, CG	, CI, CM,	UA, G	1, GQ, 2001-1	GW, ML 845738	., MK, Δ	, NE, SN, 20010430	ıb,	IG	•
AB	The instant inve		involves 1	the use	ofa	combin	ation	of prep	arat	ory	
	steps in conjun	ction w	ith mass s	spectro	scopy	and ti	me-of	f-flight	dete	ction	1
	procedures to ma										
	verifiable with verified within									litv	to
	evidence at leas									,	
	diagnostician to	gain <sup>:</sup>	the abilit	ty to o	haract	terize	eithe	er the pr	esen	ce or	•
	absence of said								ion	of th	ıe
	presence and/or were analyzed by									nd + h	
	disease specific										ie
	characterized as								L an	u	
	wt. of 1562 dal	tons was	s found.	This	narker	is ind	icati				
	myocardial infa			tive h	eart fa	ailure.					
IT	112821-21-3, Cor						e:	DOM OR			
	RL: ANT (Analyteuse); ANST (Ana	e); bsu lytical	(Biologic	cai sti	iay, ui Riologi	nciassi ical et	Tiea,	); DGN (D	nagn	05T1C	-
	(complement										
	of myocardia										
RN	112821-21-3 CAI										
CN	Complement C3f	(9CI)	(CA INDEX	NAME)							
* * *	STRUCTURE DIAGRA	N IS NO	T AVAILABI	_E ***							
IT	473552-36-2										
	RL: ANT (Analyte										
	use); PRP (Prope USES (Uses)	erties)	; ANST (Ar	nalytic	al st	udy); B	IOL (	(Biologic	al s	tudy)	;
	(complement	C3f bio	polymer ma	arker d	of 156	2 dalto	ns ir	ndicative	1		
	of myocardia								•		
RN	473552-36-2 CAI	PLUS		_							

L-Leucine, L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-

histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

L11 ANSWER 23 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833425 CAPLUS

DOCUMENT NUMBER:

137:334901

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction or renal failure

having a molecular weight of 1350

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad;

Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

```
US 2002160528
                       A1
                             20021031
                                            US 2001-845729
                                                              20010430
     WO 2002088722
                            20021107
                       A2
                                            WO 2002-CA610
                                                              20020426
     WO 2002088722
                             20021227
                       Α3
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             CM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:
                                         US 2001-845729
                                                          A 20010430
    The instant invention involves the use of a combination of preparatory
     steps in conjunction with mass spectroscopy and time-of-flight detection
     procedures to maximize the diversity of biopolymers which are
     verifiable within a particular sample. The cohort of biopolymers
     verified within such a sample is then viewed with ref. to their ability to
     evidence at least one particular disease state; thereby enabling a
     diagnostician to gain the ability to characterize either the presence or
     absence of said at least one disease state relative to recognition of the
     presence and/or the absence of said biopolymer. Serum samples
     were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the
     disease specific marker identified by the sequence SESDFLAEGGGVR and
     characterized as a .alpha. fibrinogen having a mol. wt
     . of 1350 daltons was found. This marker is indicative of myocardial
     infarction or renal failure.
     473552-35-1
IT
     RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic
     use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);
     USES (Uses)
        (alpha fibrinogen biopolymer marker of 1350 daltons
        indicative of myocardial infarction or renal failure)
RN
     473552-35-1 CAPLUS
     L-Arginine, L-seryl-L-.alpha.-glutamyl-L-seryl-L-.alpha.-aspartyl-L-
     phenylalanyl-L-leucyl-L-alanyl-L-.alpha.-glutamylglycylglycylglycyl-L-
     valyl- (9CI) (CA INDEX NAME)
```

Absolute stereochemistry.

```
HÑ.
                                        NH<sub>2</sub>
CO2H
                                        CO<sub>2</sub>H
```

L11 ANSWER 24 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833402 CAPLUS

DOCUMENT NUMBER:

137:334900

TITLE:

Complement C3f biopolymer marker indicative

of myocardial infarction and congestive heart failure having a molecular weight of 1777

daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent English

Can.

LANGUAGE: FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE		
		US 2001-845735 WO 2002-CA628			
CO, CR, GM, HR,	CU, CZ, DE, DK, HU, ID, IL, IN,	AZ, BA, BB, BG, BR, BY DM, DZ, EC, EE, ES, FI IS, JP, KE, KG, KP, KR MG, MK, MN, MW, MX, MZ	, GB, GD, GE, GH, , KZ, LC, LK, LR,		
PL, PT, UA, UG, RW: GH, GM,	RO, RU, SD, SE, UZ, VN, YU, ZA, KE, LS, MW, MZ,	SG, SI, SK, SL, TJ, TM ZM, ZW, AM, AZ, BY, KG SD, SL, SZ, TZ, UG, ZM GB, GR, IE, IT, LU, MC	, TN, TR, TT, TZ, , KZ, MD, RU, TJ, TM , ZW, AT, BE, CH,		
BF, BJ, PRIORITY APPLN. INFO AB The instant inv	<pre>CF, CG, CI, CM, .: ention involves</pre>	GA, GN, GQ, GW, ML, MR US 2001-845735 A the use of a combination	, NE, SN, TD, TG 20010430 n of preparatory		
steps in conjunction with mass spectroscopy and time-of-flight determined procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ab					
evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples					
were analyzed b disease specifi characterized a	g the Ciphergen PROTEING ied by the sequence SKI 3f fragment having a <b>mo</b> This marker is indicat	CHIP system and the THRIHWESASLL and I.			
	rction, intracer t failure.	ebral hemorrhage, Type :			
RL: ANT (Analyt	e); BSU (Biologi	cal study, unclassified	); DGN (Diagnostic		

Searched by Susan Hanley 305-4053

use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1777 daltons indicative of myocardial infarction and congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* 473546-15-5 IT RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); · (complement C3f biopolymer marker of 1777 daltons indicative of myocardial infarction and congestive heart failure) RN 473546-15-5 CAPLUS CN L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-Lisoleucyl-L-histidyl-L-tryptophyl-L-.alpha.-glutamyl-L-seryl-L-alanyl-Lseryl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

L11 ANSWER 25 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833398 CAPLUS

DOCUMENT NUMBER:

137:334899

TITLE:

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

molecular weight of 1536 daltons Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason; INVENTOR(S):

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 10 pp. CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT: 1

	CIND DATE	APPLICATION NO.	DATE
US 2002160423 A WO 2002088718 A	A2 20021107	US 2001-846780 WO 2002-CA579	20010430 20020425
CO, CR, CU, GM, HR, HU, LS, LT, LU, PL, PT, RO, UA, UG, UZ, RW: GH, GM, KE, CY, DE, DK, BF, BJ, CF, PRIORITY APPLN. INFO.:  AB The instant invention of steps in conjunction procedures to maxim verifiable within a verified within succession conjunction of steps in conjun	AM, AT, AU, AZ, AZ, CZ, DE, DK, DM, I, ID, IL, IN, IS, I, LV, MA, MD, MG, D, RU, SD, SE, SG, Y, VN, YU, ZA, ZM, E, LS, MW, MZ, SD, CG, CI, CM, GA, CI on with mass spectomize the diversity a particular samplach a sample is the one particular dispain the ability to least one disease a absence of said	SL, SZ, TZ, UG, ZM, GR, IE, IT, LU, MC, GN, GQ, GW, ML, MR, US 2001-846780 A use of a combination croscopy and time-of of biopolymers while. The cohort of ben viewed with ref. Gease state; thereby characterize either state relative to biopolymer. Serum	BZ, CA, CH, CN, GB, GD, GE, GH, KZ, LC, LK, LR, NO, NZ, OM, PH, TN, TR, TT, TZ, KZ, MD, RU, TJ, TM, ZW, AT, BE, CH, NL, PT, SE, TR, NE, SN, TD, TG 20010430 of preparatory f-flight detection ich are propolymers to their ability to y enabling a er the presence or recognition of the

disease specific marker identified by the sequence ADSGEGDFLAEGGGVR and characterized as a .alpha. fibrinogen having a mol. wt . of 1536 daltons was found. This marker is indicative of myocardial infarction.

25422-31-5, Fibrinopeptide A (human)

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1536 daltons indicative of myocardial infarction)

25422-31-5 CAPLUS RN

Fibrinopeptide A (human) (7CI, 8CI, 9CI) (CA INDEX NAME) CN

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-B

CO<sub>2</sub>H

L11 ANSWER 26 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: DOCUMENT NUMBER:

2002:833397 CAPLUS

TITLE:

137:334898

Alpha fibrinogen biopolymer marker

indicative of myocardial infarction having a

APPLICATION NO. DATE

molecular weight of 1077 daltons

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

KIND DATE

CODEN: USXXCO Patent

DOCUMENT TYPE:

INVENTOR(S):

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION: PATENT NO.

	US 2002160422	A1 · 20021031	US 2001-846342	20010430
	WO 2002088708	A2 20021107	WO 2002-CA620	20020429
	W: AE, AG,	AL, AM, AT, AU,	AZ, BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
	CO, CR,	CU, CZ, DE, DK,	DM, DZ, EC, EE, ES, FI,	GB, GD, GE, GH,
	GM, HR,	HU, ID, IL, IN,	IS, JP, KE, KG, KP, KR,	KZ, LC, LK, LR,
			MG, MK, MN, MW, MX, MZ,	
			SG, SI, SK, SL, TJ, TM,	
	UA, UG,	UZ, VN, YU, ZA,	ZM, ZW, AM, AZ, BY, KG,	KZ, MD, RU, TJ, TM
			SD, SL, SZ, TZ, UG, ZM,	
			GB, GR, IE, IT, LU, MC,	
			GA, GN, GQ, GW, ML, MR,	
	RITY APPLN. INFO		US 2001-846342 A	
AB	The instant inve	ention involves	the use of a combination	of preparatory
			spectroscopy and time-of	
			rsity of biopolymers whi	
			sample. The cohort of b	
		·	s then viewed with ref.	, -
			r disease state; thereby	
			ty to characterize eithe	
			sease state relative to	
			said biopolymer. Serum	
			g the Ciphergen PROTEINC	
			ied by the sequence GDFL	AEGGGVR and
			inogen having a mol. wt	
		is was round. T	his marker is indicative	of myocardial
	infarction.			
	473551-61-0	.) psu (p:-1:		B 611 (B)
	KL: ANI (Analyte	e); RPA (RIOIOGI	cal study, unclassified)	; DGN (Diagnostic

use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(alpha fibrinogen biopolymer marker of 1077 daltons

indicative of myocardial infarction)

RN 473551-61-0 CAPLUS

CN L-Arginine, glycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-leucyl-L-alanyl-L-.alpha.-glutamylglycylglycylglycyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

L11 ANSWER 27 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833394 CAPLUS

DOCUMENT NUMBER:

137:334897

TITLE:

Complement C3f biopolymer marker indicative

of congestive heart failure having a molecular

weight of 1793 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy Can.

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

**Patent** 

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ÚS 2002160419	A1	20021031	US 2001-845739	20010430
WO 2002088725	A2	20021107	WO 2002-CA614	20020426
WO 2002088725	A3	20030103		
W: AE, AG,	AL, AM	, AT, AU, AZ,	BA, BB, BG, BR, BY	, BZ, CA, CH, CN,
CO, CR,	CU, CZ	, DE, DK, DM,	DZ, EC, EE, ES, FI	, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG PRIORITY APPLN. INFO.: US 2001-845739 A 20010430 The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence SKITHRIHWESASLL and characterized as a complement C3f fragment having a mol. wt. of 1793 daltons was found. This marker is indicative of congestive heart failure. 112821-21-3, Complement C3f IT RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); USES (Uses) (complement C3f biopolymer marker of 1793 daltons indicative of congestive heart failure) RN 112821-21-3 CAPLUS Complement C3f (9CI) (CA INDEX NAME) CN \*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\* ΙT 473546-15-5 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study);

RN 473546-15-5 CAPLUS


of congestive heart failure)

CN L-Leucine, L-seryl-L-lysyl-L-isoleucyl-L-threonyl-L-histidyl-L-arginyl-L-isoleucyl-L-histidyl-L-tryptophyl-L-alpha.-glutamyl-L-seryl-L-alanyl-L-seryl-L-leucyl- (9CI) (CA INDEX NAME)

(complement C3f biopolymer marker of 1793 daltons indicative

Absolute stereochemistry.

PAGE 1-A



```
(CH<sub>2</sub>)<sub>4</sub>
                                                     `NH2
                                          NH2
                            HN
                                                      ОН
                       Мe
       ŅΗ
_NH
```

```
L11 ANSWER 28 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN
```

ACCESSION NUMBER:

2002:833393 CAPLUS

DOCUMENT NUMBER:

137:334896

TITLE:

Biopolymer marker indicative of Syndrome X

disease state having a molecular

weight of 1949 daltons

INVENTOR(S):

Jackowski, George; Thatcher, Brad; Marshall, John; Yantha, Jason;

Vrees, Tammy

PATENT ASSIGNEE(S):

Can.

SOURCE:

U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO Patent

DOCUMENT TYPE:

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND DAT	E A	PPLICATION NO.	DATE			
US 2002160418 WO 2002088746	A2 200	21107 W	S 2001-845727 O 2002-CA625	20010430 20020429			
CO, CR, GM, HR, LS, LT, PL, PT,	AL, AM, AT CU, CZ, DE HU, ID, IL LU, LV, MA RO, RU, SD	, AU, AZ, BA, , DK, DM, DZ, , IN, IS, JP, , MD, MG, MK, , SE, SG, SI,	EC, EE, ES, FI KE, KG, KP, KR MN, MW, MX, MZ SK, SL, TJ, TM	, BZ, CA, CH, CN, , GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ, , KZ, MD, RU, TJ, TM			
RW: GH, GM, CY, DE, BF, BJ, PRIORITY APPLN. INFO	KE, LS, MW DK, ES, FI CF, CG, CI .:	, MZ, SD, SL, , FR, GB, GR, , CM, GA, GN, US 2	SZ, TZ, UG, ZM IE, IT, LU, MC GQ, GW, ML, MR 001-845727 A	, ZW, AT, BE, CH, , NL, PT, SE, TR, , NE, SN, TD, TG 20010430			
AB The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to							
evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the							

presence and/or the absence of said biopolymer. Serum samples were analyzed by SELDI-TOF using the Ciphergen PROTEINCHIP system and the disease specific marker identified by the sequence DAHKSEVAHRFKDLGEE and characterized as a serum albumin having a mol. wt. of 1949 daltons was found. This marker is indicative of Syndrome X related diseases.

IT 473546-14-4

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(serum albumin biopolymer marker indicative of Syndrome X diseases having mol. wt. of 1949 daltons)

RN 473546-14-4 CAPLUS

N L-Glutamic acid, L-.alpha.-aspartyl-L-alanyl-L-histidyl-L-lysyl-L-seryl-L-alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl-L-lysyl-L-.alpha.-aspartyl-L-leucylglycyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

## Absolute stereochemistry.

PAGE 1-A

PAGE 1-B

PAGE 2-A

L11 ANSWER 29 OF 29 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2002:833392 CAPLUS

DOCUMENT NUMBER:

137:334895

TITLE:

Biopolymer marker indicative of disease state having a molecular weight of

1424 daltons

INVENTOR(S):

Jackowski, George; Stanton, Eric B.; Thatcher, Brad; Vrees, Tammy; Yantha, Jason; Marshall, John

PATENT ASSIGNEE(S):

SOURCE:

U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE:

Patent English

Can.

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE			
WO 2002088719	A1 20021031 A2 20021107 A3 20021227	US 2001-845726 WO 2002-CA593	20010430 20020426			
W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UA, UG, RW: GH, GM,	AL, AM, AT, AU, AZ, CU, CZ, DE, DK, DM, HU, ID, IL, IN, IS, LU, LV, MA, MD, MG, RO, RU, SD, SE, SG, UZ, VN, YU, ZA, ZM, KE, LS, MW, MZ, SD,	DZ, EC, EE, ES, FI JP, KE, KG, KP, KR MK, MN, MW, MX, MZ SI, SK, SL, TJ, TM ZW, AM, AZ, BY, KG SL, SZ, TZ, UG, ZM	, GB, GD, GE, GH, , KZ, LC, LK, LR, , NO, NZ, OM, PH, , TN, TR, TT, TZ, , KZ, MD, RU, TJ, TM , ZW, AT, BE, CH,			
BF, BJ, PRIORITY APPLN. INFO AB The instant inv	ention involves the	GN, GQ, GW, ML, MR US 2001-845726 A use of a combination	, NE, SN, TD, TG 20010430 n of preparatory			
steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with ref. to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.						
	e); DGN (Diagnostic dy); USES (Uses)	use); ANST (Analyti	cal study); BIOL			

(biopolymer marker indicative of disease state having a mol. wt. of 1424 daltons)

RN 263562-87-4 CAPLUS

CN L-Lysine, L-alanyl-L-histidyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-valyl-L-alanyl-L-histidyl-L-arginyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B